Prognostic assessment of apoptotic gene polymorphisms in non-small cell lung cancer in Chinese

Apoptosis plays a key role in inhibiting tumor growth, progression and resistance to anti-tumor therapy. We hypothesized that genetic variants in apoptotic genes may affect the prognosis of lung cancer. To test this hypothesis, we selected 38 potentially functional single nucleotide polymorphisms (SNPs) from 12 genes (BAX, BCL2, BID, CASP3, CASP6, CASP7, CASP8, CASP9, CASP10, FAS, FASLG and MCL1) involved in apoptosis to assess their prognostic significance in lung cancer in a Chinese case cohort with 568 non-small cell lung cancer (NSCLC) patients. Thirty-five SNPs passing quality control underwent association analyses, 11 of which were shown to be significantly associated with NSCLC survival (P < 0.05). After Cox stepwise regression analyses, 3 SNPs were independently associated with the outcome of NSCLC (BID rs8190315: P = 0.003; CASP9 rs4645981: P = 0.007 and FAS rs1800682: P = 0.016). A favorable survival of NSCLC was significantly associated with the genotypes of BID rs8190315 AG/GG (adjusted HR = 0.65, 95% CI: 0.49-0.88), CASP9 rs4645981 AA (HR = 0.22, 95% CI: 0.07-0.69) and FAS rs1800682 GG (adjusted HR = 0.67, 95% CI: 0.46-0.97). Time-dependent receptor operation curve (ROC) analysis revealed that the area under curve (AUC) at year 5 was significantly increased from 0.762 to 0.819 after adding the risk score of these 3 SNPs to the clinical risk score. The remaining 32 SNPs were not significantly associated with NSCLC prognosis after adjustment for these 3 SNPs. These findings indicate that BID rs8190315, CASP9 rs4645981 and FAS rs1800682 polymorphisms in the apoptotic pathway may be involved in the prognosis of NSCLC in the Chinese population.

[1]  Q. Wei,et al.  TNFRSF1B +676 T>G polymorphism predicts survival of non-Small cell lung cancer patients treated with chemoradiotherapy , 2011, BMC Cancer.

[2]  C. Kimchi-Sarfaty,et al.  Understanding the contribution of synonymous mutations to human disease , 2011, Nature Reviews Genetics.

[3]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[4]  H. Jeon,et al.  Polymorphisms in Apoptosis-Related Genes and Survival of Patients with Early-Stage Non-Small-Cell Lung Cancer , 2010, Annals of Surgical Oncology.

[5]  Hongbing Shen,et al.  A 3′-Untranslated Region Polymorphism in IGF1 Predicts Survival of Non–Small Cell Lung Cancer in a Chinese Population , 2010, Clinical Cancer Research.

[6]  Kihyun Kim,et al.  BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients. , 2010, Leukemia research.

[7]  Dong Sun Kim,et al.  Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Cotter,et al.  Apoptosis and cancer: the genesis of a research field , 2009, Nature Reviews Cancer.

[9]  A. Bankfalvi,et al.  The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  S. Kam,et al.  Polymorphisms in the FAS and FASL Genes and Survival of Early Stage Non–small Cell Lung Cancer , 2009, Clinical Cancer Research.

[11]  Boguslaw Stec,et al.  The Fas/FADD death domain complex structure unravels signaling by receptor clustering , 2008, Nature.

[12]  Ping Yang,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[13]  R. Ankathil,et al.  p53 Arg72Pro Polymorphism Predicts Survival Outcome in Lung Cancer Patients in Indian Population , 2008, Cancer investigation.

[14]  R. Kimmig,et al.  The AA Genotype of the Regulatory BCL2 Promoter Polymorphism (−938C>A) Is Associated with a Favorable Outcome in Lymph Node–Negative Invasive Breast Cancer Patients , 2007, Clinical Cancer Research.

[15]  K. Jöckel,et al.  Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. , 2007, Blood.

[16]  J. Park,et al.  Caspase 9 promoter polymorphisms and risk of primary lung cancer. , 2006, Human molecular genetics.

[17]  K. Vermeulen,et al.  Apoptosis: mechanisms and relevance in cancer , 2005, Annals of Hematology.

[18]  Sunil Singhal,et al.  Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non–Small Cell Lung Cancer: A Review , 2005, Clinical Cancer Research.

[19]  Nathaniel Rothman,et al.  Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. , 2004, Journal of the National Cancer Institute.

[20]  L. Owen-Schaub,et al.  Adenoviral Bid Overexpression Induces Caspase-dependent Cleavage of Truncated Bid and p53-independent Apoptosis in Human Non-small Cell Lung Cancers* , 2003, Journal of Biological Chemistry.

[21]  M. Brundage,et al.  Prognostic factors in non-small cell lung cancer: a decade of progress. , 2002, Chest.

[22]  T. Lumley,et al.  Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.

[23]  M. Volm,et al.  Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival , 2000, British Journal of Cancer.

[24]  M. Volm,et al.  Expression of FAS (CD95/APO‐1) and FAS ligand in lung cancer, its prognostic and predictive relevance , 1999, International journal of cancer.

[25]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[26]  Junying Yuan,et al.  Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.

[27]  C. Kitanaka,et al.  Apoptosis in cancer. , 1996, Human cell.

[28]  L. Leslie,et al.  A decade of progress. , 1969, Minnesota medicine.